● Recruiting

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Condition: Advanced Solid Tumors · Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.

PhasePhase 1/Phase 2

Planned participants220

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Yan Xu · +86 13585878226 · yan.xu@allonutshell.com

Always discuss trial participation with your own doctor first.

Locations (2)

Next Oncology	San Antonio, Texas, United States	Recruiting
Shanghai	Shanghai, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07060989